Ask AI
Back Back
ProCE Banner Activity

FAQs: Individualizing Anti-CD38–Based Quadruplet Therapy in Transplant-Eligible NDMM

Clinical Thought

In this commentary, experts address frequently asked questions about the use of CD38 quadruplets for transplant-eligible newly diagnosed multiple myeloma (NDMM), including the role of MRD-guided treatment strategies, transplant decision-making, and practical approaches to supportive care and toxicity management. The discussion also explores the evolving role of anti-CD38–based quadruplet therapy as a standard-of-care approach for fit patients with NDMM.

Released: May 19, 2026

Begin Activity

Share

Faculty

Meletios-Athanasios C. Dimopoulos

Meletios-Athanasios C. Dimopoulos, MD

Professor and Chairman
Plasma Cell Dyscrasias Unit
Section of Hematology and Medical Oncology
Department of Clinical Therapeutics
School of Medicine
National and Kapodistrian University of Athens
Alexandra Hospital
Athens, Greece
María-Victoria Mateos

María-Victoria Mateos, MD, PhD

Head of Myeloma Unit
Associate Professor
University Hospital of Salamanca
Salamanca, Spain
Philippe Moreau

Philippe Moreau, MD

Professor of Clinical Hematology
University Hospital Hotel-Dieu
Nantes, France

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

Supported by an educational grant from Sanofi Genzyme.

Sanofi Genzyme

Target Audience

This activity is intended for European bone marrow transplant specialists, hematologists, medical oncologists, and other healthcare professionals caring for patients with newly diagnosed multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Develop individualized treatments leveraging anti-CD38 antibody–based quadruplet regimens for patients with newly diagnosed MM based on current recommendations, approvals, clinical data, and patient factors ​

  • Assess the clinical utility of MRD for guiding maintenance therapy and other treatment decisions in the induction setting for patients with transplant-eligible MM

  • Plan supportive care approaches to mitigate the risk of treatment-related adverse events inpatients with newly diagnosed MM initiating treatment with anti-CD38 antibody–based quadruplet regimens​

  • Appraise emerging data for novel methods of anti-CD38 antibody administration and their implications for reducing treatment burden among patients, caregivers, and HCPs

  • Implement strategies supporting equitable access to anti-CD38 antibody–based quadruplet regimens and supportive care in underserved patients with transplant-eligible MM

Disclosure

Primary Author

Meletios-Athanasios C. Dimopoulos, MD: consultant/advisor/speaker: Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, GSK, Janssen, Menarini, Regeneron, Sanofi, Swixx, Takeda.

María-Victoria Mateos, MD, PhD: consultant/advisor/speaker: AbbVie, Amgen, Bristol Myers Squibb, GSK, Johnson & Johnson, Kite, Menarini/Stemline, Oncopeptides, Pfizer, Sanofi.

Philippe Moreau, MD, has no relevant financial relationships to disclose.